Lv3
240 积分 2021-05-21 加入
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
2天前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
3天前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
4天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
7天前
已完结
Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial
2个月前
已完结
Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation
4个月前
已完结
Axitinib or bevacizumab plus folfox or modified folfox-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study
4个月前
已完结
Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD
4个月前
已关闭
Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents
4个月前
已完结
IL-33 released during challenge phase regulates allergic asthma in an age-dependent way
4个月前
已完结
皖公网安备34019202002308
